Circulating Tumor Cells in Pancreatic Cancer: Current Perspectives

Martini, Verena; Timme-Bronsert, Sylvia; Fichtner‐Feigl, Stefan; Hoeppner, Jens; Kulemann, Birte

doi:10.3390/cancers11111659

Cited by 67 publications

(74 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The disseminated tumor cells (DTCs) and circulating tumor cells (CTCs) have been detected in the peripheral blood of many cancer types, including colorectal cancer [58], breast cancer [59], hepatocellular cancer [60] and pancreatic cancer [61][62][63]. The DTCs and CTCs in the blood could be awakened after surgery, initiating metastasis [64].…”

Section: Discussionmentioning

confidence: 99%

RETRACTED ARTICLE: Propofol inhibits migration and induces apoptosis of pancreatic cancer PANC-1 cells through miR-34a-mediated E-cadherin and LOC285194 signals

Wang¹,

Jiao²,

Jiang³

et al. 2020

Bioengineered

View full text Add to dashboard Cite

Propofol has exhibited potent antitumor activity in pancreatic cancer cells in vitro and in vivo. The study aimed to investigate the anti-tumor mechanisms of propofol on pancreatic cancer PANC-1 cells in vitro. PANC-1 cells were exposure to concentration 20 μg/ml of propofol for 72 h. Long non-coding RNA LOC285194 siRNA LOC285194 siRNA, E-cadherin siRNA and microRNA-34a (miR-34a) inhibitor were used to investigate the effect of propofol on PANC-1 cells. miR-34a and LOC285194 were analyzed by quantitative real-time PCR (qRT-PCR). Pro-apoptotic protein bax, cleaved-caspase-3 and anti-apoptotic protein bcl-2 were analyzed by Western blot. Cell viability and cell apoptosis were detected by MTT and TUNEL staining, respectively. Cell migration was detected by wound-healing assay. The results showed that propofol upregulated miR-34a expression, which, in turn, upregulated LOC285194 expression, resulting in PANC-1 cell apoptosis and growth inhibition. In addition, propofol upregulated miR-34a expression, which, in turn, upregulated E-cadherin expression, resulting in cell migration inhibition. Our research confirmed that propofol-induced cell apoptosis and inhibited cell migration in PANC-1 cells in vitro via promoting miR-34a-dependent LOC285194 and E-cadherin upregulation, respectively.

show abstract

Section: Discussionmentioning

confidence: 99%

RETRACTED ARTICLE: Propofol inhibits migration and induces apoptosis of pancreatic cancer PANC-1 cells through miR-34a-mediated E-cadherin and LOC285194 signals

Wang¹,

Jiao²,

Jiang³

et al. 2020

Bioengineered

View full text Add to dashboard Cite

show abstract

“…Circulating tumor cells (CTCs) have been evaluated as diagnostic and survival prognostic markers in patients with PDAC [ 73 ]. Peripheral CTCs represent cells originating from the primary lesion that may be undetectable by imaging tests and non-accessible to biopsy with imaging guidance [ 74 ].…”

Section: Biomarkersmentioning

confidence: 99%

Diagnostic, Predictive and Prognostic Molecular Biomarkers in Pancreatic Cancer: An Overview for Clinicians

Giannis

Moris

Barbas

2021

Cancers

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) is the most common pancreatic malignancy and is associated with aggressive tumor behavior and poor prognosis. Most patients with PDAC present with an advanced disease stage and treatment-resistant tumors. The lack of noninvasive tests for PDAC diagnosis and survival prediction mandates the identification of novel biomarkers. The early identification of high-risk patients and patients with PDAC is of utmost importance. In addition, the identification of molecules that are associated with tumor biology, aggressiveness, and metastatic potential is crucial to predict survival and to provide patients with personalized treatment regimens. In this review, we summarize the current literature and focus on newer biomarkers, which are continuously added to the armamentarium of PDAC screening, predictive tools, and prognostic tools.

show abstract

“…With the ability to enter the peripheral circulatory system, circulatory tumor cells (CTC) vary in individual and express both epithelial and mesenchymal markers [79]. It has been reported that such cells can be detected in the peripheral blood of 40% ~ 100% of pancreatic cancer patients, which may be used for the early diagnosis of pancreatic cancer [80].…”

Section: Serological Markmentioning

confidence: 99%

Advance in Pancreatic Cancer Diagnosis and Therapy

Cai¹,

Gao²,

Liu³

et al. 2021

Challenges in Pancreatic Cancer

View full text Add to dashboard Cite

Pancreatic carcinoma is the fourth leading cause of cancer death in the word wild. Although the advance in treatment this disease, the 5-years survival rate is still rather low. In the recent year, many new therapy and treatment avenues have been developed for pancreatic cancer. In this chapter, we mainly focus on the following aspect: 1) the treatment modality in pancreatic cancer, including chemotherapy, radiotherapy, and immunotherapy; 2) the mechanism of pancreatic cancer treatment resistance, especially in cancer stem cells and tumor microenvironment; 3) the diagnosis tools in pancreatic cancer, including serum markers, imaging methods and endoscopic ultrasonography. Novel molecular probes based on the nanotechnology in the diagnosis of pancreatic cancer are also discussed.

show abstract

Circulating Tumor Cells in Pancreatic Cancer: Current Perspectives

Cited by 67 publications

References 75 publications

RETRACTED ARTICLE: Propofol inhibits migration and induces apoptosis of pancreatic cancer PANC-1 cells through miR-34a-mediated E-cadherin and LOC285194 signals

RETRACTED ARTICLE: Propofol inhibits migration and induces apoptosis of pancreatic cancer PANC-1 cells through miR-34a-mediated E-cadherin and LOC285194 signals

Diagnostic, Predictive and Prognostic Molecular Biomarkers in Pancreatic Cancer: An Overview for Clinicians

Advance in Pancreatic Cancer Diagnosis and Therapy

Contact Info

Product

Resources

About